1stOncology™: Cancer Intelligence Service – Page 13175 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

On September 10, 2019 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that results from the Phase 3 ClarIDHy study of TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma have been accepted for presentation in a Presidential Symposium at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting being held September 27 – October 1, 2019 in Barcelona (Press release, Agios Pharmaceuticals, SEP 10, 2019, View Source [SID1234539425]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The schedule for the presentation by Agios is as follows:

Date & Time: Monday, September 30, 2019 from 4:30 p.m. – 4:42 p.m. CET
Title: ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation
Oral Abstract Session: Presidential Symposium III
Abstract: LBA10
Location: Barcelona Auditorium (Hall 2)
Presenter: Ghassan K. Abou-Alfa, Memorial Sloan-Kettering Cancer Center

Conference Call Information
Agios will host a conference call and live webcast with presentation slides on September 30, 2019 at 1 p.m. ET /7 p.m. CET to discuss the data from the ClarIDHy study. To participate in the conference call, please dial 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 5209309. The live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The archived webcast will be available on the company’s website beginning approximately two hours after the event.

HR Positive/ HER2 Negative Breast Cancer Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

On September 10, 2019 DelveInsight reported that it has launched Hormone Receptor positive/ Human Epidermal Receptor 2 negative Breast Cancer Market Insights, Epidemiology and Market Forecast- 2028 (Press release, Delve Insight, SEP 10, 2019, View Source [SID1234539424])

HR+/ HER2- Breast Cancer market report covers a detailed overview and comprehensive insight of the HR+ / HER2- breast cancer Epidemiology and HR+/ HER2- breast cancer market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
HR positive/ HER2 negative breast cancer market report provides insights into the current and emerging HR positive/ HER2 negative breast cancer therapies.
HR positive/ HER2 negative breast cancer market report offers a global historical and forecasted market covering drug outreach in 7 MM.
HR positive/ HER2 negative breast cancer market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Human Epidermal Receptor 2 negative Breast Cancer market.
"Among the 7MM countries, the United States had the highest HER2 negative breast cancer market size in 2017 that accounts for approximately 83.96% of the total market."

Get a free sample page: https://bit.ly/2lLQViM

At present, the growth of HR positive breast cancer market size is attributed to drugs that have been approved for Hormone Receptor positive breast cancer by the US FDA

Among the EU-5 countries, Germany had the highest HR-positive/HER2-negative breast cancer market size in 2017, which accounts for approximately 25.51% of the total market. Of the therapies prescribed as first-line breast cancer treatment, CDK4/6 inhibitors occupy the largest market share, of which Ibrance contributed the majority of the share, followed by Kisqali and Verzenio. The second position in the first-line treatment options is occupied by SERD class (Faslodex). Among the second and higher lines of therapy, CDK4/6 inhibitors occupy the largest breast cancer market share.

As the HR positive breast cancer mostly affects women. The treatment management of this specific cancer is complex and patient-centric, as treatment and outcomes differ significantly according to biomarker status among other patient characteristics, indicating a trend towards higher personalized medicine based upon patient biomarkers and physiologic characteristics.

Current treatment landscape is well-provided with treatment management. However, there is a lack of treatment and diagnostic guidelines specific to the ER-Positive breast cancer required for the management and diagnosis of ER-positive breast cancer. In recent years, there are many advancements in early detection, prevention, risk stratification, and therapeutic strategies, as well as supportive care for patients with breast cancer, and these have resulted in essential improvements in morbidity and mortality. There is a myriad of companies that are developing drugs for breast cancer treatment.

The expected launch of breast cancer emerging therapies is believed to create a positive impact on the HR positive/ HER2 negative breast cancer market size in the upcoming years.

SHR6390
TESETAXEL
RAD1901
IMMU-132
RG7440
Entinostat
MK-3475
EGL-5385-C-1701
MM-121
GSK525762 (Molibresib)
SAPANISERTIB (TAK-228)
Radium-223 dichloride
and many others
Some of the HR positive/ HER2 negative breast cancer companies are:-

Jiangsu HengRui Medicine Co.
Odonate Therapeutics
Radius Pharmaceuticals
Immunomedics
Roche Group
Syndax Pharmaceuticals
Merck Sharp & Dohme Corp
Eagle Pharmaceuticals
Merrimack Pharmaceuticals
GlaxoSmithKline
Millennium Pharmaceuticals
Bayer
and many others
Get a free demo of the report: https://bit.ly/2lLQViM

Table of contents

1. Key Insights

2. Hormone Receptor positive Breast Cancer Market Overview at a Glance

3. Human Epidermal Receptor 2 negative breast cancer Disease Background and Overview

4. HR 2 positive Epidemiology and Patient Population

5. Hormone Receptor of Positive Breast Cancer Country Wise-Epidemiology

5.1. United States

5.2. EU5 Countries

5.3. Germany

5.4. France

5.5. Italy

5.6. Spain

5.7. United Kingdom

5.8. Japan

6. Estrogen-Receptor Positive Breast Cancer Treatment

7. HER 2 negative Marketed Products

7.1. Ibrance (Palbociclib): Pfizer

7.2. PIQRAY (Alpelisib; BYL719): Novartis

7.3. Lynparza (olaparib): AstraZeneca Pharmaceuticals

7.4. Verzenio (Abemaciclib): Eli Lilly

7.5. Kisqali (Ribociclib; LEE011): Novartis Pharmaceuticals

7.6. Afinitor (Everolimus): Novartis

7.7. Faslodex (Fulvestrant) Injection: AstraZeneca

7.8. Arimidex (Anastrozole): AstraZeneca

7.9. Aromasin (Exemestane): Pharmacia and Upjohn Company

7.10. Femara (Letrozole): Novartis Pharmaceuticals

8. Unmet Needs

9. HR positive/ HER2 negative breast cancer breast cancer Emerging Drugs

9.1. Key Cross Competition

9.2. SHR6390: Jiangsu HengRui Medicine Co.

9.3. TESETAXEL: Odonate Therapeutics

9.4. RAD1901: Radius Pharmaceuticals

9.5. IMMU-132 (Sacituzumab Govitecan): Immunomedics

9.6. Ipatasertib (RG7440): Roche Group

9.7. Venclexta: Roche Group

9.8. Entinostat: Syndax Pharmaceuticals

9.9. Pembrolizumab (MK-3475): Merck Sharp and Dohme

9.10. Eribulin Mesylate: Merck Sharp & Dohme Corp.

9.11. MM-121: Merrimack Pharmaceuticals

9.12. GSK525762 (Molibresib): GlaxoSmithKline

9.13. SAPANISERTIB (TAK-228): Millennium Pharmaceuticals

9.14. Radium-223 dichloride: Bayer

9.15. EGL-5385-C-1701(fulvestrant): Eagle Pharmaceuticals

10. HR+/HER2- Post Menopause Breast Cancer Market Analysis (7MM)

11. The United States HR positive/ HER2 negative breast cancer Market Analysis

11.1. The United States HR positive/ HER2 negative breast cancer Market Outlook

11.2. United States HR positive/ HER2 negative breast cancer Market Size

12. EU-5 HR positive/ HER2 negative breast cancer Market Analysis

12.1. EU-5 HR positive/ HER2 negative breast cancer Market Outlook

12.2. Germany HR positive/ HER2 negative breast cancer Market Size

12.3. France HR positive/ HER2 negative breast cancer Market Size

12.4. Italy HR positive/ HER2 negative breast cancer Market Size

12.5. Spain HR positive/ HER2 negative breast cancer Market Size

12.6. The United Kingdom HR positive/ HER2 negative breast cancer Market Size

13. Japan Market Outlook

14. Market Drivers

15. Market Barriers

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

Caris Life Sciences to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

On September 10, 2019 Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, reported that Brian J. Brille, Vice Chairman of the Company, will present at the 17th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019, at 12:55 p.m. Eastern Time (Press release, Caris Life Sciences, SEP 10, 2019, View Source [SID1234539423]). The conference is being held at The Grand Hyatt Hotel in New York City.

Mr. Brille will provide an overview of the business and discuss recent corporate achievements that position Caris to further extend its leadership in the market, in addition to taking questions from the audience.

Investors attending the conference who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Morgan Stanley representative.

Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program

On September 10, 2019 Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company developing novel drugs and biologics, reported that it has been selected by the National Cancer Institute (NCI) as one of three contractors in response to the solicitation for the PREVENT Cancer Preclinical Drug Development Program (PREVENT): Current Good Manufacturing Practice (cGMP) Production of Vaccines and Biologicals for Cancer Prevention (cGMP Pool) (Press release, Kindred Healthcare, SEP 10, 2019, View Source [SID1234539421]). As a cGMP pool contractor, KindredBio is eligible to provide manufacturing, formulation and analytical services to meet the needs of the PREVENT pipeline.

PREVENT is an NCI-supported venture to advance preclinical development of innovative cancer prevention interventions and biomarkers towards clinical applications. A maximum amount of $49.95 million will be shared across three contract pools, one of which is the cGMP manufacturing pool. Within the cGMP pool, KindredBio is one of three contractors selected for award. The contract term is four years, with specific amounts based on individual task order awards yet to be determined.

"This selection is a validation of our manufacturing and project management expertise, and we look forward to working with the NCI on this important program," said Richard Chin, CEO of KindredBio.

KindredBio operates a state-of-the-art biological development and cGMP manufacturing facility in Burlingame, CA, and recently completed construction on a 180,000 square foot large scale cGMP manufacturing facility in Elwood, KS.

The company’s core expertise includes protein engineering, cell line development, master cell banking, process development, assay development, stability testing, and cGMP clinical and commercial manufacturing. KindredBio’s biologics team comprises experts in product development, manufacturing, quality control and quality assurance personnel, and is supported by a strong project management organization.

For additional information on PREVENT, please click here. Task orders awarded to KindredBio are expected to be conducted at the company’s cGMP manufacturing facility in Burlingame, CA.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91019D00027.

RegeneRx to Present at Fall Investor Summit on September 17

On September 10, 2019 RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, reported that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Fall Investor Summit on September 17, 2019, at 8:30 a.m. ET in New York City (Press release, RegeneRx Biopharmaceuticals, SEP 10, 2019, View Source [SID1234539420]). The presentation will be webcast and can be accessed by the following link: View Source A slide presentation will also be available on the Company’s website at: View Source